US biopharma Apellis (Nasdaq: APLS) has announced a company restructuring in a bid to focus on making Syfovre (pegcetacoplan injection) a leading treatment for geographic atrophy (GA).
Apellis says that the restructuring will result in up to $300 million in total cost savings through 2024.
Cedric Francois, co-founder and chief executive of Apellis, said, “We are taking important actions to strengthen our ability to invest in growth opportunities and support the company's long-term success, including maximizing the significant opportunity with Syfovre.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze